ダカルバジン
Based on 15 publication(s) in Google Scholar
Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.96%
- CAS 番号: 4342-03-4
- 分子式: C6H10N6O
- 分子量:182.18
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Lung Cancer Compound Library
HY-L075
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Tumorigenesis-Related Compound Library
HY-L100
-
Pediatric Drug Library
HY-L104
-
Chemotherapy Drug Library
HY-L112
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
MedChemExpress（MCE）の使用を引用している文献 Dacarbazine
More- Nature. 2023 Jun;618(7964):374-382. [Abstract]
- Nat Commun. 2024 Sep 10;15(1):7923. [Abstract]
- Adv Sci (Weinh). 2024 Dec;11(48):e2408707. [Abstract]
- Theranostics. 2020 Jul 25;10(21):9477-9494. [Abstract]
- J Nanobiotechnology. 2023 Oct 19;21(1):383. [Abstract]
- Carbohydr Polym. 2024 Dec 15:346:122645. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Cell Death Dis. 2025 Apr 9;16(1):268. [Abstract]
- Phytother Res. 2024 Jun;38(6):2800-2817. [Abstract]
- J Ethnopharmacol. 2024 Apr 24:324:117759. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Heliyon. 2024 Jan 18;10(3):e24988. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- J Cancer Res Clin Oncol. 2025 Dec 17;152(1):12. [Abstract]
- SSRN. 2024 Mar 20.
Customer Validation & Images
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
>100 μM
Compound: DTIC
|
Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
|
[PMID: 20056548] |
| A-375 | IC50 |
>100 μM
Compound: DTIC, dacarbazine
|
Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
|
[PMID: 18477505] |
| A-375 | IC50 |
>500 μM
Compound: dacarbazine
|
Cytotoxicity against human A375 cells after 48 hrs by MTT assay
Cytotoxicity against human A375 cells after 48 hrs by MTT assay
|
[PMID: 22560315] |
| A549 | IC50 |
35 μg/mL
Compound: Dacarbazine
|
Cytotoxicity against Homo sapiens (human) A549 cells assessed as cell viability by MTT assay
Cytotoxicity against Homo sapiens (human) A549 cells assessed as cell viability by MTT assay
|
10.1007/s00044-007-9031-x |
| B16-F1 | IC50 |
>100 μM
Compound: DTIC
|
Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
|
[PMID: 20056548] |
| B16-F1 | IC50 |
>100 μM
Compound: DTIC, dacarbazine
|
Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
|
[PMID: 18477505] |
| Fibroblast | IC50 |
>100 μM
Compound: DTIC
|
Cytotoxicity against human fibroblasts after 48 hrs by SRB assay
Cytotoxicity against human fibroblasts after 48 hrs by SRB assay
|
[PMID: 20056548] |
| HeLa | GI50 |
>50 μM
Compound: DTIC
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay
|
[PMID: 24986661] |
| MDA-MB-435 | GI50 |
84.33 μM
Compound: Dacarbazine
|
Growth inhibition of human MDA-MB-435 cells measured after 24 to 72 hrs by SRB method
Growth inhibition of human MDA-MB-435 cells measured after 24 to 72 hrs by SRB method
|
[PMID: 37163949] |
| OVCAR-3 | IC50 |
17.67 μM
Compound: Dacarbazine
|
Cytotoxicity against human OVCAR3 cells after 6 days by MTT assay
Cytotoxicity against human OVCAR3 cells after 6 days by MTT assay
|
[PMID: 21131205] |
| Raji | IC50 |
128 μM
Compound: DTIC
|
In vitro cytotoxicity against Raji cell line
In vitro cytotoxicity against Raji cell line
|
[PMID: 7739008] |
| SK-MEL-2 | IC50 |
120 μM
Compound: Dacarbazine
|
Cytotoxicity against human SK-MEL-2 cells after 6 days by MTT assay
Cytotoxicity against human SK-MEL-2 cells after 6 days by MTT assay
|
[PMID: 21131205] |
| SK-MEL-28 | GI50 |
>100 μM
Compound: Dacarbazine
|
Growth inhibition of human SK-MEL-28 cells measured after 24 to 72 hrs by SRB method
Growth inhibition of human SK-MEL-28 cells measured after 24 to 72 hrs by SRB method
|
[PMID: 37163949] |
| UACC-62 | IC50 |
11.83 μM
Compound: Dacarbazine
|
Cytotoxicity against human UACC62 cells after 6 days by MTT assay
Cytotoxicity against human UACC62 cells after 6 days by MTT assay
|
[PMID: 21131205] |
| WM164 | IC50 |
>100 μM
Compound: DTIC
|
Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
|
[PMID: 17561392] |
| WM164 | IC50 |
>100 μM
Compound: DTIC
|
Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
|
[PMID: 20056548] |
Dacarbazine (6.25-500 μg/mL 48 h) combines with hyperthermia-induced cytotoxicity of A375 and MNT-1 melanoma cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A375, MNT-1
-
Concentration:6.25, 12.5, 25, 50, 100, 200, 400, 500 μg/mL
-
Incubation Time:24, 48, 72 h
-
Result:Inhibited cell viability in a concentration-dependent manner.
-
Cell Line:A375, MNT-1
-
Concentration:5.5, 115 μg/mL
-
Incubation Time:48 h
-
Result:Decreased (9.3%) the percentage of A375 cells at the S phase and increased the number of cells at G2/M.
Decreased MNT-1 cells at G0/G1, increasing in cells at both S and G2/M phases.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 4342-03-4
-
性状 Solid
-
分子量 182.18
-
分子式 C6H10N6O
-
Color White to yellow
-
SMILES
O=C(C1=C(/N=N/N(C)C)NC=N1)N
-
別名
Dacarbazine; Imidazole Carboxamide
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Nature
2023 Jun;618(7964):374-382. PMID: 37225988
Dacarbazine purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7964):374-382. [Abstract]
Dacarbazine (60 mg/kg; i.p.; every other day for 8 d) significantly reduced red blood cell (RBC), reticulocyte (RET), and hemoglobin (HGB) counts in PBS- or B16F10-CL-EVP-educated mice.
-
Nat Commun
2024 Sep 10;15(1):7923. PMID: 39256387 -
Adv Sci (Weinh)
Patient-Derived Melanoma Immune-Tumoroids as a Platform for Precise High throughput Drug Screening. [Abstract]2024 Dec;11(48):e2408707. PMID: 39475010
Dacarbazine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec;11(48):e2408707. [Abstract]
Dacarbazine (DTIC) (500 µM; 72 h) reduced the diameter and metabolic activity of MCTs except monoculture tumoroids, especially the triples and quadruples, resulting in a decrease of approximately 32% and 28% in relative diameter, respectively, and caused a high number of apoptotic cells to detach from the main structure.
-
Theranostics
Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. [Abstract]2020 Jul 25;10(21):9477-9494. PMID: 32863940 -
J Nanobiotechnology
Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma. [Abstract]2023 Oct 19;21(1):383. PMID: 37858186
Dacarbazine purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2023 Oct 19;21(1):383. [Abstract]
Dacarbazine (DAC) (5 mg/kg; i.v.; once every three days for 3 times) significantly inhibited the growth of subcutaneous B16F10 melanoma xenografts in C57BL/6 mice.
Dacarbazine purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2023 Oct 19;21(1):383. [Abstract]
H&E staining of tumors in each group at the end of treatment. The results showed that Dacarbazine (DAC) (5 mg/kg; i.v.; once every three days for 3 times) caused significant cell necrosis and nucleopaenia in tumors of B16F10 tumor-bearing mice. Scale bar, 100 μm.
-
Carbohydr Polym
Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma. [Abstract]2024 Dec 15:346:122645. PMID: 39245506 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Cell Death Dis
MTCH2 regulates NRF2-mediated RRM1 expression to promote melanoma proliferation and dacarbazine insensitivity. [Abstract]2025 Apr 9;16(1):268. PMID: 40204724
Dacarbazine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 9;16(1):268. [Abstract]
Dacarbazine (20 mg/kg; i.p.; 20 d) reduced tumor growth rates and tumor sizes of melanoma xenograft mice.
-
Phytother Res
Isoalantolactone exerts anti-melanoma effects via inhibiting PI3K/AKT/mTOR and STAT3 signaling in cell and mouse models. [Abstract]2024 Jun;38(6):2800-2817. PMID: 38526171 -
J Ethnopharmacol
Screening of anti-melanoma compounds from Morus alba L.: Sanggenon C promotes melanoma cell apoptosis by disrupting intracellular Ca2+ homeostasis. [Abstract]2024 Apr 24:324:117759. PMID: 38219884 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Heliyon
2024 Jan 18;10(3):e24988. PMID: 38317912 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
J Cancer Res Clin Oncol
Comprehensive analysis based on spatial domains identifies CD44 as a potential target of puerarin. [Abstract]2025 Dec 17;152(1):12. PMID: 41405724 -
溶剤 & 溶解度
0.1 M HCl : 20 mg/mL (109.78 mM; ultrasonic and warming and heat to 60°C)
DMSO : 5 mg/mL (27.45 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (10.98 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (27.45 mM); Suspended solution; Need ultrasonic
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Serrone, L., et al., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res, 2000. 19(1): p. 21-34. [Content Brief]
[2]. Al-Badr AA, et al. Dacarbazine. Profiles Drug Subst Excip Relat Methodol. 2016;41:323-77. [Content Brief]
[3]. Rojo JM, et al. Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio. Chemotherapy. 1983;29(5):345-51. [Content Brief]
[4]. Erdmann S, et al. Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. Sci Rep. 2019 Jan 10;9(1):30. [Content Brief]
[5]. Salvador D, et al. Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells. Int J Mol Sci. 2022 Mar 25;23(7):3586. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 0.1 M HCl | 1 mM | 5.4891 mL | 27.4454 mL | 54.8908 mL | 137.2269 mL |
| 5 mM | 1.0978 mL | 5.4891 mL | 10.9782 mL | 27.4454 mL | |
| 10 mM | 0.5489 mL | 2.7445 mL | 5.4891 mL | 13.7227 mL | |
| 15 mM | 0.3659 mL | 1.8297 mL | 3.6594 mL | 9.1485 mL | |
| 20 mM | 0.2745 mL | 1.3723 mL | 2.7445 mL | 6.8613 mL | |
| 25 mM | 0.2196 mL | 1.0978 mL | 2.1956 mL | 5.4891 mL | |
| 0.1 M HCl | 30 mM | 0.1830 mL | 0.9148 mL | 1.8297 mL | 4.5742 mL |
| 40 mM | 0.1372 mL | 0.6861 mL | 1.3723 mL | 3.4307 mL | |
| 50 mM | 0.1098 mL | 0.5489 mL | 1.0978 mL | 2.7445 mL | |
| 60 mM | 0.0915 mL | 0.4574 mL | 0.9148 mL | 2.2871 mL | |
| 80 mM | 0.0686 mL | 0.3431 mL | 0.6861 mL | 1.7153 mL | |
| 100 mM | 0.0549 mL | 0.2745 mL | 0.5489 mL | 1.3723 mL |
Powered by Bioz